Arsenic trioxide
- Generic Name
- Arsenic trioxide
- Brand Names
- Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
- Drug Type
- Small Molecule
- Chemical Formula
- As2O3
- CAS Number
- 1327-53-3
- Unique Ingredient Identifier
- S7V92P67HO
- Background
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
- Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Associated Conditions
- Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2010-08-11
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT00720564
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
- Conditions
- Myelodysplastic Syndromes and Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT00671697
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
- Conditions
- Acute Promyelocytic Leukemia
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT00670150
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
- Conditions
- Multiple MyelomaStem Cell Transplantation
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00661544
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2014-01-08
- Lead Sponsor
- Duke University
- Target Recruit Count
- 25
- Registration Number
- NCT00590603
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2016-02-19
- Target Recruit Count
- 9
- Registration Number
- NCT00582400
- Locations
- 🇺🇸
University of Texas Medical Branch at Galveston, Galveston, Texas, United States
Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 21
- Registration Number
- NCT00572065
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 9
- Registration Number
- NCT00571116
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 78
- Registration Number
- NCT00551460
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸Saint Louis University Cancer Center, Saint Louis, Missouri, United States
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00528450
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.